EX-99.1 2 ea029540901ex99-1.htm PRESS RELEASE, DATED JUNE 18, 2026 Exhibit 99.1 Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June 18, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121) - a differentiated, dual PARP and WNT pathway inhibitor - today announced that it will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, held June 17 - 19 in Copenhagen, Denmark. The poster outlines the scientific background, study design, and clinical rationale for the Company’s ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The study builds directly on Allarity’s prior Phase 2 clinical experience, including the durable clinical benefit observed in heavily pretreated ovarian cancer patients. As a Trial-in-Progress presentation, the pos…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Allarity Therapeutics, Inc.
Other Events
Item 8.01 Other Matters. On June 22, 2026, Allarity Therapeutics, Inc. (the “Company”) announced its presentation of a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026, which was held June 17 - 19, 2026, in Copenhagen, Denmark. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Company context
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.